Submitted:
01 September 2024
Posted:
03 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Participants
2.2. Study Design
2.3. Sample Analysis
2.3.1. Plasma Oxylipins and Statistical Procedures
2.3.2. Plasma Proteome
2.3.3. Urine Untargeted Metabolomics Analysis and Statistical Procedures
2.3.4. Gut Microbiome Analysis and Statistical Procedures: DNA Isolation
2.3.4.1. Illumina Whole Genome Shotgun (WGS) Sequencing [40]
2.3.4.2. Bioinformatics
2.4. Additional Statistical Procedures
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Nieman, D.C.; Lila, M.A.; Gillitt, N.D. Immunometabolism: A multi-omics approach to interpreting the influence of exercise and diet on the immune system. Annu Rev Food Sci Technol. 2019, 10, 341–363. [Google Scholar] [CrossRef] [PubMed]
- Blumberg, J.B.; Camesano, T.A.; Cassidy, A.; Kris-Etherton, P.; Howell, A.; Manach, C.; et al. Cranberries and their bioactive constituents in human health. Adv Nutr. 2013, 4, 618–632. [Google Scholar] [CrossRef]
- Nemzer, B.V.; Al-Taher, F.; Yashin, A.; Revelsky, I.; Yashin, Y. Cranberry: Chemical composition, antioxidant activity and impact on human health: overview. Molecules. 2022, 27, 1503. [Google Scholar] [CrossRef]
- Balawejder, M.; Piechowiak, T.; Kapusta, I.; Chęciek, A.; Matłok, N. In vitro analysis of selected antioxidant and biological properties of the extract from large-fruited cranberry fruits. Molecules. 2023, 28, 7895. [Google Scholar] [CrossRef]
- Taibi, A.; Lofft, Z.; Laytouni-Imbriaco, B.; Comelli, E.M. The role of intestinal microbiota and microRNAs in the anti-inflammatory effects of cranberry: from pre-clinical to clinical studies. Front Nutr. 2023, 10, 1092342. [Google Scholar] [CrossRef] [PubMed]
- de Souza Gouveia Moreira, L.; Resende Teixeira, K.T.; Cardozo, L.F.M.F.; Alvarenga, L.; Regis, B.; Sousa de Brito, J.; et al. Effects of cranberry extract (Vaccinium macrocarpon) supplementation on lipid peroxidation and inflammation in patients with chronic kidney disease (stages 3-4): A randomized controlled trial. J Nutr Metab. 2024, 2024, 9590066. [Google Scholar] [CrossRef] [PubMed]
- Chew, B.; Mathison, B.; Kimble, L.; McKay, D.; Kaspar, K.; Khoo, C.; et al. Chronic consumption of a low calorie, high polyphenol cranberry beverage attenuates inflammation and improves glucoregulation and HDL cholesterol in healthy overweight humans: a randomized controlled trial. Eur J Nutr. 2019, 58, 1223–1235. [Google Scholar] [CrossRef] [PubMed]
- Hsia, D.S.; Zhang, D.J.; Beyl, R.S.; Greenway, F.L.; Khoo, C. Effect of daily consumption of cranberry beverage on insulin sensitivity and modification of cardiovascular risk factors in adults with obesity: a pilot, randomised, placebo-controlled study. Br J Nutr. 2020, 124, 577–585. [Google Scholar] [CrossRef]
- Lessard-Lord, J.; Roussel, C.; Lupien-Meilleur, J.; Généreux, P.; Richard, V.; Guay, V.; et al. Short term supplementation with cranberry extract modulates gut microbiota in human and displays a bifidogenic effect. NPJ Biofilms Microbiomes. 2024, 10, 18. [Google Scholar] [CrossRef]
- Déprez, S.; Brezillon, C.; Rabot, S.; Philippe, C.; Mila, I.; Lapierre, C.; Scalbert, A. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J Nutr. 2000, 130, 2733–2738. [Google Scholar] [CrossRef]
- Straub, T.J.; Chou, W.C.; Manson, A.L.; Schreiber, H.L., 4th; Walker, B.J.; Desjardins, C.A.; et al. Limited effects of long-term daily cranberry consumption on the gut microbiome in a placebo-controlled study of women with recurrent urinary tract infections. BMC Microbiol. 2021, 21, 53. [Google Scholar] [CrossRef] [PubMed]
- Prieto Martínez, A.; Coutiño Diaz, M.; Anaya Romero, L.; Ali Redha, A.; Zare, R.; Ventura Hernandez, S.; et al. Effects of Vaccinium berries (blueberries, cranberries and bilberries) on oxidative stress, inflammation, exercise performance, and recovery - a systematic review. Food Funct. 2024, 15, 444–459. [Google Scholar] [CrossRef]
- Skarpańska-Stejnborn, A.; Basta, P.; Trzeciak, J.; Michalska, A.; Kafkas, M.E.; Woitas-Ślubowska, D. Effects of cranberry (Vaccinum macrocarpon) supplementation on iron status and inflammatory markers in rowers. J Int Soc Sports Nutr. 2017, 14, 7. [Google Scholar] [CrossRef] [PubMed]
- Parenteau, F.; Denis, A.; Roberts, M.; Comtois, A.S.; Bergdahl, A. A polyphenol-rich cranberry supplement improves muscle oxidative capacity in healthy adults. Appl Physiol Nutr Metab. 2024, 49, 1047–1054. [Google Scholar] [CrossRef] [PubMed]
- Parenteau, F.; Puglia, V.F.; Roberts, M.; Comtois, A.S.; Bergdahl, A. Cranberry supplementation improves physiological markers of performance in trained runners. Phys Act Nutr. 2023, 27, 8–14. [Google Scholar] [CrossRef] [PubMed]
- Nieman, D.C. Multiomics approach to precision sports nutrition: limits, challenges, and possibilities. Front Nutr. 2021, 8, 796360. [Google Scholar] [CrossRef]
- Nieman, D.C.; Sakaguchi, C.A.; Omar, A.M.; Davis, K.L.; Shaffner, C.E.; Strauch, R.C.; et al. Blueberry intake elevates post-exercise anti-inflammatory oxylipins: a randomized trial. Sci Rep. 2023, 13, 11976. [Google Scholar] [CrossRef]
- Nieman, D.C.; Woo, J.; Sakaguchi, C.A.; Omar, A.M.; Tang, Y.; Davis, K.; et al. Astaxanthin supplementation counters exercise-induced decreases in immune-related plasma proteins. Front Nutr. 2023, 10, 1143385. [Google Scholar] [CrossRef]
- Nieman, D.C.; Omar, A.M.; Kay, C.D.; Kasote, D.M.; Sakaguchi, C.A.; Lkhagva, A.; et al. Almond intake alters the acute plasma dihydroxy-octadecenoic acid (DiHOME) response to eccentric exercise. Front Nutr. 2023, 9, 1042719. [Google Scholar] [CrossRef]
- Nieman, D.C.; Gillitt, N.D.; Chen, G.Y.; Zhang, Q.; Sha, W.; Kay, C.D.; et al. Blueberry and/or banana consumption mitigate arachidonic, cytochrome p450 oxylipin generation during recovery from 75-km cycling: a randomized trial. Front Nutr. 2020, 7, 121. [Google Scholar] [CrossRef]
- Nieman, D.C.; Gillitt, N.D.; Chen, G.Y.; Zhang, Q.; Sakaguchi, C.A.; Stephan, E.H. Carbohydrate intake attenuates post-exercise plasma levels of cytochrome P450-generated oxylipins. PLoS One. 2019, 14, e0213676. [Google Scholar] [CrossRef]
- Nieman, D.C.; Gillitt, N.D.; Sha, W.; Esposito, D.; Ramamoorthy, S. Metabolic recovery from heavy exertion following banana compared to sugar beverage or water only ingestion: A randomized, crossover trial. PLoS One. 2018, 13, e0194843. [Google Scholar] [CrossRef] [PubMed]
- Nieman, D.C.; Gillitt, N.D.; Henson, D.A.; Sha, W.; Shanely, R.A.; Knab, A.M.; et al. Bananas as an energy source during exercise: a metabolomics approach. PLoS One. 2012, 7, e37479. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.-Y.; Zhang, Q. Comprehensive analysis of oxylipins in human plasma using reversed-phase liquid chromatography-triple quadrupole mass spectrometry with heatmap-assisted selection of transitions. Anal Bioanal Chem. 2019, 411, 367–385. [Google Scholar] [CrossRef] [PubMed]
- Nieman, D.C.; Sakaguchi, C.A.; Williams, J.C.; Mulani, F.A.; Suresh, P.S.; Omar, A.M.; Zhang, Q. Beet supplementation mitigates post-exercise inflammation. Front Nutr. 2024, 11, 1408804. [Google Scholar] [CrossRef]
- Woo, J.; Zhang, Q. A streamlined high-throughput plasma proteomics platform for clinical proteomics with improved proteome coverage, reproducibility, and robustness. J Am Soc Mass Spectrom. 2023, 34, 754–762. [Google Scholar] [CrossRef]
- Demichev, V.; Messner, C.B.; Vernardis, S.I.; Lilley, K.S.; Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020, 17, 41–44. [Google Scholar] [CrossRef]
- Geyer, P.E.; Arend, F.M.; Doll, S.; Louiset, M.-L.; Virreira Winter, S.; Müller-Reif, J.B.; et al. High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion. EMBO Mol Med. 2021, 13, e14167. [Google Scholar] [CrossRef]
- Pathmasiri, W.; Rushing, B.R.; McRitchie, S.; Choudhari, M.; Du, X.; Smirnov, A.; et al. Untargeted metabolomics reveal signatures of a healthy lifestyle. Sci Rep. 2024, 14, 13630. [Google Scholar] [CrossRef]
- Li, Y.Y.; Ghanbari, R.; Pathmasiri, W.; McRitchie, S.; Poustchi, H.; Shayanrad, A.; et al. Untargeted metabolomics: biochemical perturbations in golestan cohort study opium users inform intervention strategies. Front Nutr. 2020, 7, 584585. [Google Scholar] [CrossRef]
- Ghanbari, R.; Li, Y.; Pathmasiri, W.; McRitchie, S.; Etemadi, A.; Pollock, J.D.; et al. Metabolomics reveals biomarkers of opioid use disorder. Transl Psychiatry. 2021, 11, 103. [Google Scholar] [CrossRef] [PubMed]
- Lynch, D.H.; Rushing, B.R.; Pathmasiri, W.; McRitchie, S.; Batchek, D.J.; Petersen, C.L.; et al. Baseline serum biomarkers predict response to a weight loss intervention in older adults with obesity: A pilot study. Metabolites. 2023, 13, 853. [Google Scholar] [CrossRef]
- Sun, J.; Xia, Y. Pretreating and normalizing metabolomics data for statistical analysis. Genes Dis. 2023, 11, 100979. [Google Scholar] [CrossRef]
- Välikangas, T.; Suomi, T.; Elo, L.L. A systematic evaluation of normalization methods in quantitative label-free proteomics. Brief Bioinform. 2018, 19, 1–11. [Google Scholar] [CrossRef]
- Smirnov, A.; Liao, Y.; Fahy, E.; Subramaniam, S.; Du, X. ADAP-KDB: A spectral knowledgebase for tracking and prioritizing unknown GC-MS spectra in the NIH's Metabolomics Data Repository. Anal Chem. 2021, 93, 12213–12220. [Google Scholar] [CrossRef]
- Lynch, D.H.; Rushing, B.R.; Pathmasiri, W.; McRitchie, S.; Batchek, D.J.; Petersen, C.L.; et al. Baseline serum biomarkers predict response to a weight loss intervention in older adults with obesity: a pilot study. Metabolites. 2023, 13, 853. [Google Scholar] [CrossRef]
- Azcarate-Peril, M.A.; Butz, N.; Cadenas, M.B.; Koci, M.; Ballou, A.; Mendoza, M.; et al. An attenuated salmonella enterica serovar typhimurium strain and galacto-oligosaccharides accelerate clearance of salmonella infections in poultry through modifications to the gut microbiome. Appl Environ Microbiol. 2018, 84, e02526–17. [Google Scholar] [CrossRef] [PubMed]
- Arnold, J.W.; Whittington, H.D.; Dagher, S.F.; Roach, J.; Azcarate-Peril, M.A.; Bruno-Barcena, J.M. Safety and modulatory effects of humanized galacto-oligosaccharides on the gut microbiome. Front Nutr. 2021, 8, 640100. [Google Scholar] [CrossRef]
- Marsh, A.J.; Yaya, A.-M.A.; Ng, S.; Chandrashekhar, K.; Roach, J.; Magness, S.T.; Azcarate-Perilet, M.A. Lumen and mucosa-associated Lactobacillus rhamnosus from the intestinal tract of organ donors. Gut Microbiome. 2020, 1, e4. [Google Scholar] [CrossRef]
- Sun, S.; Zhu, X.; Huang, X.; Murff, H.J.; Ness, R.M.; Seidner, D.L.; et al. On the robustness of inference of association with the gut microbiota in stool, rectal swab and mucosal tissue samples. Sci Rep. 2021, 11, 14828. [Google Scholar] [CrossRef]
- Seth-Smith, H.M.B.; Bonfiglio, F.; Cuénod, A.; Reist, J.; Egli, A.; Wüthrich, D. Evaluation of rapid library preparation protocols for whole genome sequencing based outbreak investigation. Front Public Health. 2019, 7, 241. [Google Scholar] [CrossRef]
- Wood, D.E.; Lu, J.; Langmead, B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019, 20, 257. [Google Scholar] [CrossRef]
- Lu, J.; Breitwieser, F.P.; Thielen, P.; Salzberg, S.L. Bracken: estimating species abundance in metagenomics data. PeerJ Comp Sci. 2017, 3, e104. [Google Scholar] [CrossRef]
- Rognes, T.; Flouri, T.; Nichols, B.; Quince, C.; Mahé, F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016, 4, e2584. [Google Scholar] [CrossRef] [PubMed]
- Abubucker, S.; Segata, N.; Goll, J.; Schubert, A.M.; Izard, J.; Cantarel, B.L.; et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol. 2012, 8, e1002358. [Google Scholar] [CrossRef]
- Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019, 37, 852–857. [Google Scholar] [CrossRef]
- Stull, A.J.; Cassidy, A.; Djousse, L.; Johnson, S.A.; Krikorian, R.; Lampe, J.W.; et al. The state of the science on the health benefits of blueberries: a perspective. Front Nutr. 2024, 11, 1415737. [Google Scholar] [CrossRef]
- Kondža, M.; Brizić, I.; Jokić, S. Flavonoids as CYP3A4 inhibitors in vitro. Biomedicines. 2024, 12, 644. [Google Scholar] [CrossRef] [PubMed]
- Andersen-Civil, A.I.S.; Leppä, M.M.; Thamsborg, S.M.; Salminen, J.P.; Williams, A.R. Structure-function analysis of purified proanthocyanidins reveals a role for polymer size in suppressing inflammatory responses. Commun Biol. 2021, 4, 896. [Google Scholar] [CrossRef]
- Alejo-Armijo, A.; Salido, S.; Altarejos, J.N. Synthesis of A-type proanthocyanidins and their analogues: A comprehensive review. J Agric Food Chem. 2020, 68, 8104–8118. [Google Scholar] [CrossRef]
- Rauf, A.; Imran, M.; Abu-Izneid, T.; Iahtisham-Ul-Haq Patel, S.; Pan, X.; et al. Proanthocyanidins: A comprehensive review. Biomed Pharmacother. 2019, 116, 108999. [Google Scholar] [CrossRef]
- González de Llano, D.; Roldán, M.; Taladrid, D.; Relaño de la Guía, E.; Moreno-Arribas, M.V.; Bartolomé, B. Cranberry polyphenols and prevention against urinary tract infections: new findings related to the integrity and functionality of intestinal and urinary barriers. J Agric Food Chem. 2024, 72, 10328–10338. [Google Scholar] [CrossRef] [PubMed]
- Maki, K.C.; Kaspar, K.L.; Khoo, C.; Derrig, L.H.; Schild, A.L.; Gupta, K. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection. Am J Clin Nutr. 2016, 103, 1434–1442. [Google Scholar] [CrossRef]
- Nieman, D.C.; Groen, A.J.; Pugachev, A.; Vacca, G. Detection of functional overreaching in endurance athletes using proteomics. Proteomes. 2018, 6, 33. [Google Scholar] [CrossRef] [PubMed]
- Gao, T.; Hou, M.; Zhang, B.; Pan, X.; Liu, C.; Sun, C.; et al. Effects of cranberry beverages on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial. Food Funct. 2021, 12, 6878–6888. [Google Scholar] [CrossRef]
- Rodríguez-Morató, J.; Matthan, N.R.; Liu, J.; de la Torre, R.; Chen, C.O. Cranberries attenuate animal-based diet-induced changes in microbiota composition and functionality: a randomized crossover controlled feeding trial. J Nutr Biochem. 2018, 62, 76–86. [Google Scholar] [CrossRef]
- Othaim, A.A.; Marasini, D.; Carbonero, F. Impact of cranberry juice consumption on gut and vaginal microbiota in postmenopausal women. Food Front. 2021, 2, 282–293. [Google Scholar] [CrossRef]
- Neto, C.C.; Mortzfeld, B.M.; Turbitt, J.R.; Bhattarai, S.K.; Yeliseyev, V.; DiBenedetto, N.; et al. Proanthocyanidin-enriched cranberry extract induces resilient bacterial community dynamics in a gnotobiotic mouse model. Microb Cell. 2021, 8, 131–142. [Google Scholar] [CrossRef]






| Sex | Mean±SE | |
| Age (yrs) | M | 43.2±2.2 |
| F | 41.8±2.9 | |
| Weight (kg) | M | 79.8±2.5* |
| F | 61.4±4.0 | |
| Height (cm) | M | 178±0.9* |
| F | 165±2.4 | |
| BMI (kg/m2) | M | 25.2±0.7* |
| F | 22.4±1.1 | |
| Body fat (%) | M | 22.1±1.7 |
| F | 26.0±3.6 | |
| V02max (ml.kg.-1min-1) | M | 46.2±2.1* |
| F | 37.4±2.1 | |
| Max watts | M | 269±7.3* |
| F | 216±22.1 | |
| Max heart rate (beats/min) | M | 172±2.1 |
| F | 165±3.4 | |
| Max ventilation (L/min) | M | 136±5.5* |
| F | 83.1±4.7 | |
| Max respiratory rate (breaths/min) | M | 46.6±2.2 |
| F | 45.0±1.6 |
| Performance Measurement | Mean±SE | |
| Cycling power (watts, % maximum) |
Cranberry | 159±7.2 (62.8±1.7% max) |
| Placebo | 153±6.9 (60.9±2.0% max) | |
| Heart rate (beats/min, % maximum) |
Cranberry | 133±2.3 (78.5±1.5% max) |
| Placebo | 134±2.9 (78.7±1.7% max) | |
| Oxygen consumption (VO2) (ml.kg.-1min-1, % maximum) | Cranberry | 29.8±1.3 (69.1±1.7% max) |
| Placebo | 28.6±1.3 (66.6±2.3% max) | |
| Distance cycled (km) | Cranberry | 61.2±2.7 |
| Placebo | 61.6±2.0 | |
| Speed (km/h) | Cranberry | 27.5±0.8 |
| Placebo | 26.5±0.9 | |
| Variable (ng/ml) | Trial | Pre- Suppl. |
4-Wks Suppl. |
0h Post-Ex |
1.5h Post-Ex |
3h Post-Ex |
24h Post-Ex |
P- value |
|---|---|---|---|---|---|---|---|---|
| Arachidonic acid (ARA) | CRAN | 1122±68.1 | 1084±65.5 | 2592±151 | 2015±74.8 | 910±49.9 | 1009±52.5 | <0.001; 0.027 |
| PLAC | 1050±61.0 | 1015±56.3 | 2467±123 | 1719±72.4 | 829±40.3 | 1029±44.3 | ||
| Docosahexaenoic acid (DHA) | CRAN | 323±40.3 | 336±41.8 | 932±81.3 | 748±65.1 | 264±32.7 | 314±42.4 | <0.001; 0.183 |
| PLAC | 336±45.3 | 278±25.1 | 858±87.6 | 622±56.7 | 218±19.4 | 297±29.7 | ||
| Eicosapentaenoic acid (EPA) | CRAN | 278±41.8 | 284±51.3 | 687±90.9 | 548±77.9 | 238±34.2 | 288±63.6 | <0.001; 0.104 |
| PLAC | 292±64.3 | 214±20.1 | 617±72.5 | 417±46.4 | 189±17.1 | 239±27.0 | ||
| Oxylipins, total (n=53 oxylipins) | CRAN | 46.5±4.3 | 45.0±2.6 | 94.3±7.6 | 76.7±5.8 | 54.0±3.0 | 42.3±2.6 | <0.001; 0.189 |
| PLAC | 47.9±3.2 | 43.8±2.6 | 92.9±7.6 | 65.4±4.2 | 47.4±2.3 | 44.0±2.6 | ||
| ARA-CYP† (n=8 oxylipins) | CRAN | 7.2±0.7 | 6.6±0.4 | 12.7±1.2 | 16.5±1.9 | 13.6±1.5 | 6.6±0.4 | <0.001; 0.446 |
| PLAC | 6.3±0.3 | 6.4±0.4 | 12.9±1.9 | 15.0±2.2 | 12.3±1.5 | 7.1±0.5 | ||
| LA-CYP DiHOMES (9,10+12,13) †† | CRAN | 3.2±0.3 | 4.8±0.5 | 12.4±1.5 | 6.6±1.0 | 5.6±0.4 | 4.2±0.6 | <0.001; 0.022 |
| PLAC | 4.7±0.6 | 3.7±0.4 | 11.6±1.2 | 6.2±0.7 | 5.5±0.4 | 4.3±0.6 | ||
| LA-LOX HODES (9+13) ††† | CRAN | 5.4±0.5 | 6.6±0.5 | 17.6±1.7 | 10.8±1.2 | 5.3±0.5 | 6.1±0.6 | <0.001; 0.008 |
| PLAC | 6.6±0.6 | 5.5±0.5 | 17.0±1.5 | 8.9±0.8 | 4.8±0.3 | 6.0±0.7 |
| Protein | 2-way ANOVA p value supplement effect |
# of interactions |
|---|---|---|
| Cathepsin D (CTSD): degrades proteins and activates precursors of bioactive proteins in pre-lysosomal compartments. | <0.0001 | 4 |
| Complement factor H related 1 (CFHR1): involved in regulating innate immune complement reactions. | 0.0003 | 8 |
| Protein C inhibitor, plasminogen activator inhibitor-3 (SERPINA5): serine protease inhibitor that limits protein C. | 0.0078 | 5 |
| Complement component C6 (C6): a complement system protein involved in the membrane attack complex (MAC). | 0.0083 | 11 |
| Protein disulfide isomerase family A member 3 (PDIA3): chaperone protein that mediates protein folding. | 0.0108 | 5 |
| Plasminogen (PLG): dissolves the fibrin of blood clots; proteolytic factor in a variety of other processes including inflammation. | 0.0117 | 12 |
| Complement component C8 alpha chain A (C8A): Constituent of MAC that plays a key role in innate and adaptive immune responses. | 0.0131 | 9 |
| Carboxypeptidase B2 (CPB2): Down-regulates fibrinolysis. | 0.0144 | 12 |
| Coagulation factor XII (F12): initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. | 0.0164 | 8 |
| Mannan-binding lectin serine protease 2 (MASP2): Serum protease involved in complement system activation. | 0.0186 | 9 |
| Protein | 2-way ANOVA p value supplement effect |
# of interactions |
|---|---|---|
| Heat shock protein family A (Hsp70) member 5 (HSPA5): HSP70 chaperone involved in the folding and assembly of proteins in the endoplasmic reticulum. | <0.0001 | 5 |
| Complement component C3 (C3): central role in the activation of the complement system. | <0.0001 | 11 |
| Metalloproteinase inhibitor 1 (TIMP1): inhibitor of the matrix metalloproteinases (MMPs), a group of peptidases involved in degradation of the extracellular matrix. | 0.0001 | 9 |
| Serpin family A member 10 (SERPINA10): inhibits the activity of coagulation factors Xa and XIa in the presence of protein Z, calcium and phospholipid. | 0.0002 | 5 |
| Hemoglobin subunit beta (HBB): involved in oxygen transport from the lung to the various peripheral tissues. | 0.0009 | 5 |
| Alpha-2-macroglobulin (A2M): protease inhibitor; inhibits inflammatory cytokines and disrupts inflammatory cascades. | 0.0012 | 14 |
| Calreticulin (CALR): calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum. | 0.0025 | 5 |
| Orosomucoid 2 (ORM2): acute-phase reactant. | 0.0026 | 8 |
| Clusterin (CLU): involved in numerous processes including regulation of complement active and the clearance of cellular debris and apoptosis. | 0.0067 | 12 |
| Haptoglobin-related protein (HPR): associated with apolipoprotein L-I (apoL-I)-containing high-density lipoprotein (HDL). | 0.0087 | 12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).